Complete heart block secondary to bortezomib use in multiple myeloma

Abstract

Although rare, cardiac rhythm abnormalities have been documented with bortezomib use in clinical trials. These side effects must be recognized promptly by physicians of various specialties as well as pharmacists. Special attention is required in patients with liver function abnormalities, elderly and patients with pre-existing cardiac conditions. Prompt bortezomib withdrawal is essential in these cases as it may prevent dismal outcomes. This is the first report of a complete heart block caused by bortezomib in the setting of myeloma therapy outside a clinical trial. The author discusses further various heart rhythm and other autonomic nervous system abnormalities attributed to bortezomib in the existing literature.

Keywords

complete heart block bortezomib autonomic nervous system cardiac rhythm arrhythmia

Get full access to this article

View all access options for this article.

References

Cavaletti G. , Gilardini A. , Canta A. , Rigamonti L. , Rodriguez-Menendez V. , Ceresa C. , et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007; 204: 317-325.

Richardson PG , Briemberg H. , Jagannath S. , Wen PY , Barlogie B. , Berenson J. , et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-3120.

Reece DE , Sanchorawala V. , Hegenbart U. , Merlini G. , Palladini G. , Fermand JP , et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489-1497.

Hacihanefioglu A. , Tarkun P. , and Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 2008; 88: 219-222.

Shah MH , Young D. , Kindler HL , Webb I. , Kleiber B. , Wright J. , et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10: 6111-6118.

Waller JM , Moretto JC , and Knopf KB Multiple significant bortezomib-related toxicities in one patient: case report and literature review. Clin Lymphoma Myeloma 2009; 9: E1-E4.

Berenson JR , Jagannath S. , Barlogie B. , Siegel DT , Alexanian R. , Richardson PG , et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104: 2141-2148.